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Abstract
Background: The National Institute for Health and Care Excellence (NICE) have called for research into the role of
biomarkers, and specifically procalcitonin (PCT), for the early diagnosis of serious bacterial infections (SBI) in children.
The aim of this study was to compare the diagnostic test accuracy of C-reactive protein (CRP) and PCT for the
diagnosis of SBI in children.
Methods: Data was collected prospectively from four UK emergency departments (ED) between November 2017
and June 2019. Consecutive children under 18 years of age with fever and features of possible sepsis and/or
meningitis were eligible for inclusion. The index tests were PCT and CRP and the reference standard was the
confirmation of SBI.
Results: 213 children were included in the final analysis. 116 participants (54.5%) were male, and the median age
was 2 years, 9 months. Parenteral antibiotics were given to 100 (46.9%), three (1.4%) were admitted to a paediatric
intensive care unit and there were no deaths. There were ten (4.7%) confirmed SBI. The area under the curve for
PCT and CRP for the detection of SBI was identical at 0.70.
Conclusions: There was no difference in the performance of PCT and CRP for the recognition of SBI in this cohort.
Trial registration: Registered at https://www.clinicaltrials.gov (trial registration: NCT03378258) on the 19th of
December 2017.
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Background
Serious bacterial infections (SBI) can be difficult to dis-
tinguish from many self-limiting benign viral infections
affecting children, especially during the prodrome. When
the diagnosis is unclear, clinicians may use biomarkers,
such as C-reactive protein (CRP) and procalcitonin
(PCT), to aid clinical decision-making [1]. Procalcitonin
is the precursor for calcitonin and is produced by paraf-
ollicular cells [2, 3]. It is a 116-amino acid protein that
has roles in calcium metabolism [4]. PCT is elevated
during infection and typically rises within two hours of
the onset of a bacterial infection reaching a peak at 24
to 36 hours [4]. Procalcitonin levels are attenuated by
the presence of interferon gamma that is typically re-
leased during viral infections leading to suggestions that
PCT may have uses in distinguishing viral from bacterial
infections [4].
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The existing literature regarding the test accuracy of PCT
in children is favourable with at least five meta-analyses
demonstrating that PCT is accurate when used to diagnosis
SBI across a range of paediatric settings [5–9]. The two
most commonly used PCT cut-offs are 0.5 ng/ml and
2.0 ng/ml [5–9]. The lower cut-off of 0.5 ng/ml typically
provides an approximate 80% sensitivity for the identifica-
tion of SBI whereas the higher cut-off of 2.0 ng/ml typically
provides a specificity of around 90% [5–9]. Two of the five
meta-analyses compared PCT to CRP with both studies
reporting that PCT was more accurate than CRP for the
diagnosis of SBI in children [8, 9]. PCT has also been
shown to be particularly useful in the assessment of febrile
young infants under 90 days of age [10–12].
As technology evolves, there is increasing interest in
the use of point-of-care (POC) biomarkers for the early
recognition of SBI. There have been a number of studies
exploring the use of POC CRP testing to identify SBI at
presentation to healthcare [13, 14]. These studies have
reported that the use of POC CRP can help to risk strat-
ify children at triage/initial assessment [13]. Procalcito-
nin testing may however, represent the ideal POC test
for detecting SBI in children due to its greater test
accuracy.
The purpose of this sub-analysis of the Petechiae in
Children (PiC) study was to report the diagnostic test
accuracy of POC PCT for the diagnosis of SBI in chil-
dren presenting to the Emergency Department (ED).
Methods
The PiC study was a mixed method prospective, multi-
centre cohort study, for which the full protocol is avail-
able as an open access publication [15]. The PiC study
was designed and reported in line with the Standards for
Reporting Diagnostic accuracy studies (STARD) state-
ment [16].
Participants
Consecutive children under 18 years of age (initially lim-
ited to 14 years but extended to 18 years following an
amendment) attending Emergency Departments (ED)
with reported or recorded fever (≥ 38 °C) and features of
meningococcal infection, sepsis, or meningitis with
blood available for PCT testing were eligible for inclu-
sion. Features of meningococcal infection included a
non-blanching rash or a global assessment of likely sep-
sis/meningitis based on National Institute for Health
and Care Excellence (NICE) guidance CG120 [17].
Children with pre-existing conditions predisposing to
non-blanching rashes were excluded as were participants
who were screened after admission when reference tests
had already been performed. Participants for this sub-
analysis were enrolled between the 9th of November
2017 and the 30th of June 2019 at four EDs in the UK
(recruitment by site can be found in Table 1).
Test methods
The PCT index test was performed using the commer-
cially available BRAHMS IB10 PCT test, on 0.5 ml of
whole blood collected in Lithium Heparin paediatric
blood bottles during routine phlebotomy. Samples were
tested as soon as possible after collection using the Sam-
sung LABEGO IB10 analyser, housed in the ED. The
stepwise procedure involved pipetting 0.5 ml of the sam-
ple into the test disc before loading this onto the ana-
lyser and pressing run. The total run time for each
sample was 20 minutes. In all instances the index test
was performed prior to the reference standard results
being available. The PCT result was not made available
for use in the child’s clinical care. The CRP testing was
performed in accredited NHS laboratories as part of the
child’s routine investigations.
Reference standard
The reference standard was the diagnosis of a serious
bacterial infection (SBI), the criteria for which are de-
tailed below based on previously published definitions
[5–10]. The reference standard tests were performed
blinded to the result of the index tests except for clinical
diagnoses such as cellulitis where an independent refer-
ence test does not exist.
 Septicaemia (including bacteraemia): pathogenic
bacteria isolated from blood culture or polymerase
chain reaction (PCR).
 Bacterial Meningitis: Identification of bacteria in
cerebrospinal fluid using culture or PCR.
 Appendicitis: confirmed on histology.
 Pneumonia: infiltrate on chest X-ray confirmed by
consultant radiologist.
 Osteomyelitis: pathogens from bone aspirate, or
MRI or bone scan suggestive of osteomyelitis.
 Cellulitis: acute suppurative inflammation of
subcutaneous tissues.
 Bacterial gastroenteritis: pathogen isolated from
stool culture.
 Complicated urinary tract infection: >105/mL
pathogens of a single species isolated from urine
culture and systemic effects such as fever.
Follow up
Researchers at each site checked attendance records
seven days after enrolment to monitor for any un-
planned re-attendances by study participants. Where this
occurred it was logged along with any change of
diagnosis.
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Analysis
The study population was described in terms of demo-
graphic characteristics. Simple descriptive statistics (total
number and proportion) were used to describe vaccin-
ation status, parenteral antibiotic use, admission to in-
tensive care units, and survival. The diagnostic accuracy
of PCT and CRP at a range of cut-points was reported
as sensitivity, specificity, negative predictive value
(NPV), positive predictive value (PPV) and negative/
positive likelihood ratios (LHR), with 95% confidence
intervals (CI). The area under the curve (AUC) was
calculated for both PCT and CRP. Patients where the
index test PCT was not performed were excluded
from analysis.
Consent Model
Due to the potentially life-threatening nature of SBI a re-
search without prior consent (RWPC) model was used
as described in detail elsewhere [18]. All participants
were invited to provide written consent at the earliest
appropriate opportunity once the child’s clinical condi-
tion had stabilised (typically within 24 hours of enrol-
ment). All participants were free to decline consent
without suffering any detriment.
Data Management
Study data were collected and managed using REDCap
(Research Electronic Data Capture) [19]. Copies of the
case report forms are available in the supplementary
material.
Public and patient involvement (PPI)
PPI was integral within the PiC study from its outset.
The PPI group assisted in its design including the proto-
col, study information, and RWPC methodology.
Office for Research Ethics Committees (OREC) and local
Research Governance
The study was approved by both the Northern Ireland
OREC (Project ID 224,660, OREC ID 17/NI/0169) and
by the Belfast Health and Social Care Trust Research
Governance.
Study Registration
The PiC study was registered at https://www.clinical-
trials.gov (trial registration: NCT03378258) on the 19th
of December 2017.
Results
A total of 327 consecutive children were screened for
eligibility across the four sites, of which 25 were ineli-
gible and 89 did not have sufficient blood available for
PCT testing (Fig. 1). Amongst the 89 with insufficient
blood available for PCT testing there were four serious
bacterial infections (4.5%). The SBI comprised of one
case of septicaemia, one urinary tract infection and two
children with pneumonia.
A total of 213 children were included in the final ana-
lysis. Reference standard testing was performed in all
but four participants; all four were diagnosed with a viral
illness, were discharged, and did not re-attend. 116
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participants (54.5%) were male, and the median age
was 2 years, 9 months (range 1 month − 13 years,
11 months), with 166 (77.9%) aged five years or youn-
ger. A total of 208 (97.8%) were appropriately vacci-
nated for age according to the UK vaccination
schedule. Parenteral antibiotics were given to 100
(46.9%), three (1.4%) were admitted to a paediatric in-
tensive care unit (PICU), and there were no deaths.
There were ten (4.7%) confirmed SBI (Table 1). The
AUC for PCT and CRP for the detection of SBI were
identical at 0.70 (p = 1.00). The sensitivity, specificity,
predictive values and LHR of CRP and PCT over a
range of values are presented in Tables 2 and 3.
There were no adverse events reported in association
with the index testing.
Discussion
In this study there was no difference in the performance
of PCT and CRP for the recognition of SBI amongst fe-
brile children attending the ED. In this cohort both CRP
and PCT demonstrated an AUC of 0.70 (p = 1.00). The
findings presented here are strikingly similar to those of
Verbakel et al. who reported on over 5000 children from
Belgium using a similar study design [13]. In that study
the rate of SBI was 4.9% and the AUC for CRP was 0.76,
though they did not examine PCT [13]. These data sug-
gest that in low prevalence settings, such as the ED, that
the indiscriminate use of PCT/CRP in febrile children is
of limited value.
PCT may however be useful in other settings. Specifically
for use in the assessment of febrile infants under 90 days of
Fig. 1 Flow of participants through the study
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age and in the assessment of suspected sepsis [8, 10, 12]. In
these settings PCT has been shown to consistently outper-
form CRP as the biomarker of choice (8.10,12). Further
studies to explore the use of POC PCT in these settings
would be welcome.
Although the presented data are from a small co-
hort of patients, the study was well designed and ad-
herent to STARD standards with prospective data
collection and blinding with regards to reference
standard testing. The data reflect the real-world per-
formance of PCT and CRP when used widely in fe-
brile children attending the ED.
This study has a number of limitations however, the
study was small with a low numbers of children with
SBI. Within the SBIs there was an over representation of
septicaemia (four) and cellulitis (three) with an under
representation of pneumonia (zero). This likely reflects
the study population and that most presented with a
fever and rash or other symptoms of possible meningo-
coccal infection.
The study was also limited by the high proportion of
children without sufficient blood for PCT testing (n =
89). The population without sufficient blood for testing
was similar to that of the overall study population with
four SBIs (4.5%). This suggests that the reasons for not
testing were due to the challenges of paediatric phlebot-
omy rather than any bias based on illness severity. In
addition, the majority of recruited patients were from a
single site and that most were under five years of age.
The findings should be cautiously interpreted, as they are
not applicable to higher SBI prevalence settings such as in-
patients or intensive care and are not applicable in cases of
pneumonia or in infants under three months of age.
Conclusions
Serious bacterial infections are often difficult to differen-
tiate from viral infections during the prodrome. It has
been suggested that PCT may be superior to CRP for
the diagnosis of SBIs in children [8–10]. The data pre-
sented here suggests that PCT and CRP both have only
a moderate accuracy for detecting serious bacterial infec-
tions when use indiscriminately in febrile children at-
tending the emergency department.














0.25 0.80(0.44 to 0.96) 0.62(0.55 to 0.69) 0.98(0.93 to 1.00) 0.10(0.05 to 0.19) 0.32(0.09 to 1.12) 2.12(0.48 to 3.00)
0.50 0.70(0.35 to 0.92) 0.65(0.58 to 0.72) 0.98(0.93 to 1.00) 0.10(0.05 to 0.19) 0.46(0.18 to 1.19) 2.02(1.28 to 3.16)
0.75 0.60(0.27 to 0.86) 0.81(0.74 to 0.86) 0.98(0.93 to 0.99) 0.14(0.06 to 0.29) 0.49(0.23 to 1.06) 3.13(1.75 to 5.61)
1.00 0.60(0.27 to 0.86) 0.84(0.78 to 0.89) 0.98(0.93 to 0.99) 0.16(0.07 to 0.33) 0.48(0.22 to 1.02) 3.74(2.05 to 6.81)
1.25 0.60(0.27 to 0.86) 0.88(0.82 to 0.92) 0.98(0.93 to 0.99) 0.20(0.08 to 0.39) 0.46(0.21 to 0.98) 4.83(2.57 to 9.05)
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1.75 0.50(0.20 to 0.80) 0.91(0.85 to 0.94) 0.97(0.93 to 0.99) 0.22(0.08 to 0.44) 0.55(0.30 to 1.03) 5.36(2.51 to 11.46)
2.00 0.40(0.14 to 0.73) 0.92(0.87 to 0.95) 0.97(0.93 to 0.99) 0.20(0.07 to 0.44) 0.65(0.39 to 1.09) 4.83(1.98 to 11.80)
CI Confidence Interval














10 0.90(0.54 to 0.99) 0.40(0.33 to 0.48) 0.99(0.92 to 1.00) 0.07(0.04 to 0.14) 0.25(0.04 to 1.61) 1.51(1.19 to 1.91)
20 0.70(0.35 to 0.92) 0.52(0.45 to 0.59) 0.97(0.91 to 0.99) 0.07(0.04 to 0.14) 0.58(0.22 to 1.51) 1.45(0.94 to 2.24)
30 0.60(0.27 to 0.86) 0.63(0.55 to 0.69) 0.97(0.92 to 0.99) 0.08(0.03 to 0.17) 0.64(0.30 to 1.37) 1.61(0.94 to 2.75)
50 0.50(0.20 to 0.80) 0.78(0.72 to 0.84) 0.97(0.92 to 0.99) 0.11(0.04 to 0.24) 0.64(0.34 to 1.19) 2.30(1.17 to 4.51)
75 0.40(0.14 to 0.73) 0.87(0.81 to 0.91) 0.97(0.92 to 0.99) 0.13(0.04 to 0.32) 0.69(0.42 to 1.15) 2.97(1.28 to 6.87)
100 0.40(0.14 to 0.73) 0.93(0.89 to 0.96) 0.97(0.92 to 0.99) 0.24(0.08 to 0.50) 0.64(0.39 to 1.07) 5.94(2.36 to 14.95)
150 0.20(0.04 to 0.56) 0.97(0.94 to 0.99) 0.96(0.92 to 0.98) 0.29(0.05 to 0.70) 0.82(0.60 to 1.12) 7.72(1.70 to 35.00)
200 0.10(0.01 to 0.46) 0.99(0.96 to 1.00) 0.96(0.91 to 0.98) 0.33(0.02 to 0.87) 0.91(0.74 to 1.12) 9.65(0.95 to 97.7)
CI Confidence Interval
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